Skip to Main Content

Author Details

Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
2016
73
22
PMIDPaper TitleJournal TitlePublished Year
36635225First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma.J Pathol Clin Res2023
37758351Response to "NGS, the New Global Standard?"J Thorac Oncol2023
37713929Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.ESMO Open2023
37586177Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.Lung Cancer2023
37292089Is iron deficiency caused by <i>BMPR2</i> mutations or dysfunction in pulmonary arterial hypertension patients?Pulm Circ2023
37059713Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis.Cell Death Discov2023
37141769Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.Lung Cancer2023
37327584Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD).Transl Oncol2023
36852573Real-world data for precision cancer medicine-A European perspective.Genes Chromosomes Cancer2023
36738930Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.J Thorac Oncol2023
34331337Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.Genes Chromosomes Cancer2022
35384413Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.J Pathol Clin Res2022
35598358The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.Eur J Cancer2022
35681079Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).NPJ Precis Oncol2022
35871236Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.Br J Cancer2022
36207130Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.Cold Spring Harb Mol Case Stud2022
35986087Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.Br J Cancer2022
36387148Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors.Front Oncol2022
33631297Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling.Semin Cancer Biol2022
34907344p53 partial loss-of-function mutations sensitize to chemotherapy.Oncogene2022
34997651Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications.Genes Chromosomes Cancer2022
35058282Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report.Cold Spring Harb Mol Case Stud2022
34125345Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.Cancer Immunol Immunother2022
34164264Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.Transl Lung Cancer Res2021
33686791KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.Genes Chromosomes Cancer2021
33520406A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma.Oncoimmunology2021
33898315<i>De Novo</i> Versus Secondary Metastatic <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer.Front Oncol2021
33508231Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets.Cell2021
33667718Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.Lung Cancer2021
34408792Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.Ther Adv Med Oncol2021
34487971The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.ESMO Open2021
34536122GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.Acta Neuropathol2021
33938987[Variant interpretation in molecular pathology and oncology : An introduction].Pathologe2021
34012783Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.Transl Lung Cancer Res2021
33959513Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer.Front Oncol2021
34090172Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer.ESMO Open2021
33976623Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.Case Rep Oncol2021
34307143Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma.Front Oncol2021
30358615Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56.Appl Immunohistochem Mol Morphol2020
31970771Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.Int J Cancer2020
31652375Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.Genes Chromosomes Cancer2020
32003543Microproteomics and Immunohistochemistry Reveal Differences in Aldo-Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's Disease.Proteomics Clin Appl2020
33087321YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF/c-MET Signaling in Liver Tumorigenesis.Cancer Res2020
33161228Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.EBioMedicine2020
32119917Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.J Thorac Oncol2020
32212351Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing.Genes Chromosomes Cancer2020
32143116Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.Lung Cancer2020
32319699NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays.Genes Chromosomes Cancer2020
32129943Automated sample preparation with SP3 for low-input clinical proteomics.Mol Syst Biol2020
31601699Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes.J Nucl Med2020
  • 1 - 50 of 73

Recommended Authors

Majd Al Assaad
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2018
Number of shared co-authors 0
Xue Wu
Nanjing Geneseeq Technology Inc.
Career Start Year 2016
Number of shared co-authors 0
David A Moore
University College London Cancer Institute
Career Start Year 2012
Number of shared co-authors 3
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 2012
Number of shared co-authors 2
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 0
Siddhartha Devarakonda
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2011
Number of shared co-authors 1
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 0
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 6
Vibha Raghavan
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2009
Number of shared co-authors 0
Charlotte K Y Ng
University of Bern
Career Start Year 2009
Number of shared co-authors 2
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 2
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 1
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 0
Francine B de Abreu
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 0
Iacopo Petrini
University of Pisa
Career Start Year 2006
Number of shared co-authors 0
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 5
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 3
David Neil Hayes
Center for Cancer Research, University of Tennessee Health Science Center
Career Start Year 1999
Number of shared co-authors 1
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 2
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 7
Patrick Micke
Uppsala University
Career Start Year 1997
Number of shared co-authors 0
Prudence A Russell
St Vincent's Hospital
Career Start Year 1997
Number of shared co-authors 2
Siraj M Ali
Foundation Medicine
Career Start Year 1995
Number of shared co-authors 2
Gregory J Riely
Memorial Sloan Kettering Cancer Center
Career Start Year 1994
Number of shared co-authors 1
Matthew Meyerson
Broad Institute
Career Start Year 1983
Number of shared co-authors 13
Hira Rizvi
Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Career Start Year 1978
Number of shared co-authors 1
Hans Brunnstr??m
Lund University
Career Start Year 1977
Number of shared co-authors 0
Ming-Sound Tsao
University Health Network, University of Toronto
Career Start Year 1972
Number of shared co-authors 1

Collaborators

Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 59
Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 39
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 25
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 25
Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 24
Michael Allg??uer
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 23
Anna-Lena Volckmar
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 20
Olaf Neumann
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 15
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 14
Holger S??ltmann
German Cancer Research Center (DKFZ)
Co-authored papers 9
Markus Ball
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 6
Huriye Seker-Cin
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 5
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 4
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Co-authored papers 4
Susanne Beck
Vrije Universiteit Brussel (VUB)
Co-authored papers 4
Thomas Longerich
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 3
Hannah Goldschmid
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 3
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Co-authored papers 2
Charles Swanton
Francis Crick Institute
Co-authored papers 2
Stephanie Roessler
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 2
Alex H Wagner
Iowa State University, Mayo Clinic, Nationwide Children's Hospital, The Ohio State University College of Medicine, University of Iowa, Washington University in Saint Louis
Co-authored papers 2
David Capper
Charite University Medicine Berlin
Co-authored papers 2
Andreas von Deimling
Co-authored papers 2
Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Co-authored papers 2
Martin Sill
Co-authored papers 2
Matthias Schlesner
University of Augsburg
Co-authored papers 2
Holger Moch
University Hospital Zurich
Co-authored papers 1
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Co-authored papers 1
Tomasz Zemojtel
Berlin Institute of Health (BIH)
Co-authored papers 1
David T W Jones
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 1
Release 1.2